ライフサイエンスコーパス: infusion

1 imit the applicability of O2 carriers during infusion.

2 ower body negative pressure and rapid saline infusion.

3 locity were recorded at rest and during drug infusion.

4 unlikely to be related or not related to MIC infusion.

5 ns during water infusion relative to glucose infusion.

6 mpathoexcitatory PVN neurons following AngII infusion.

7 neurohormonal stimulation via Angiotensin II infusion.

8 6-12 months posttransplant received the cell infusion.

9 encephalography (MEG) gamma power 6-9 h post-infusion.

10 ks and their potential relationship with the infusion.

11 e contributions to the CAR-T cell pool after infusion.

12 ts to their immune function after CAR-T-cell infusion.

13 rs that can be ablated by retrograde ethanol infusion.

14 is highest in the IPs and declines following infusion.

15 750-1350 mg orally, or a 600-mg intravenous infusion.

16 from alcohol over the 21 days after ketamine infusion.

17 cal trials as a highly concentrated systemic infusion.

18 sis in cirrhosis and is reduced with albumin infusion.

19 nine (both P < 0.005) following 72-h glucose infusion.

20 omparison with commercial forest fruits (FF) infusion.

21 iting toxicities occurring within 4 weeks of infusion.

22 quantitative signal change post-ferumoxytol infusion.

23 ormal convective O(2) delivery) with nitrite infusion.

24 arginine bolus before and after 72-h glucose infusion.

25 aged with diffusion MRI before and after the infusion.

26 usion were comparable with the commercial FF infusion.

27 sional or self-administered) via intravenous infusion.

28 c bioprocessing and addition of green coffee infusion.

29 mbilical cord blood mononuclear cell (hUCBC) infusion.

30 d their effects on the safety of intravenous infusions.

31 Right kidneys received vehicle infusions.

32 r infants and young children, tea and herbal infusions.

33 el resilience when administering intravenous infusions.

34 and increased errors across phases after DLS infusions.

35 ely to receive TOL-TAZ as an extended 3-hour infusion (0% vs. 29%; p=0.04).

36 ression (TRD) who received a single ketamine infusion (0.5 mg/kg) over 40 min.

37 ined them to lever press for methamphetamine infusions (12 d).

38 teraction (6 d) and then for methamphetamine infusions (12 d).

39 d proportions of CD4+ T cells 24 hours after infusions 2, 3, and 4 (median -3.5% to -4.5%) vs. placeb

40 ding dose (200 mg/kg) followed by continuous infusion (300 mg/kg per day) until discharge.

41 p to 10 cycles of AMG 420 were given (4-week infusions/6-week cycles).

42 symptoms within 3 days of administration of infusion; 87% vs 56%).

43 therapies included the following: vasoactive infusions (88%), central venous catheters (86%), mechani

44 nhibit their spiking activity during glucose infusion, a GLP-1r-dependent function.

45 A continuous infusion administration strategy may be superior to inte

46 Here, we studied how VRC01 infusions affected viral rebound after cessation of anti

47 advantages and disadvantages for the direct infusion analysis of atmospheric aerosol extracts.

48 s adverse events in the period between first infusion and data cutoff.

49 s, pigs and dogs during constant intravenous infusion and euglycemic clamp conditions.

50 Four T cell receptors (TCRs) made up the TIL infusion and recognized two KRAS-G12D neoantigens, a non

51 himeric antigen receptor T cell (CAR T cell) infusion and represent a therapeutic challenge.

52 thod to evaluate the antioxidant capacity of infusions and beverages, based on superoxide radicals.

53 a discrete choice procedure between fentanyl infusions and palatable food (20 trials/d).

54 rley, cow milk, vegetable drinks, tea, plant infusions and plant mixtures.

55 etermine the acute (via [13C6]-phenylalanine infusion) and longer-term (ingestion of deuterated water

56 rolled; 17 had sufficient edited T cells for infusion, and 12 were able to receive treatment.

57 ion was inhibited after 2 h of noradrenaline infusion, and both catecholamines promoted monocyte and

58 ge within the standard duration of adenosine infusion, and increased the magnitude and reliability of

59 R-T-cell infusion, immediate post CAR-T-cell infusion, and long-term follow-up.

60 events, as they occurred before CAR-NKT cell infusion, and no dose-limiting toxicities were observed.

61 marrow biopsies were obtained 14-24 h after infusion, and the percentage of administered activity wa

62 d errors in the intermediate phase after DMS infusions, and increased errors across phases after DLS

63 transcranial magnetic stimulation, ketamine infusions, and, more recently, glabellar botulinum toxin

64 imiR-21 (10 mg) was applied by intracoronary infusion at days 5 and 19 after the injury.

65 xpanded ex vivo and administered in a single infusion at one of three doses (1x10(5), 1x10(6), or 1x1

66 time, significantly predicted SSI (<24.6 min infusion, AUC = 0.762).

67 Hence, this infusion-based glaucoma model exhibits graded neural dam

68 and in-hospital tranexamic acid (1 g) 8-hour infusion (bolus maintenance group; n = 312), out-of-hosp

69 d (2 g) bolus and in-hospital placebo 8-hour infusion (bolus only group; n = 345), and out-of-hospita

70 common in the administration of intravenous infusions, but not all result in negative consequences.

71 atients exposed to catecholamine vasopressor infusions, but unaffected by sedatives.

72 ion strategy may be superior to intermittent infusion by minimizing peak concentrations and variabili

73 ther show that ctDNA dynamics after a single infusion can aid in identification of patients who will

74 d be caused by trauma from air flow from the infusion cannula during the air-gas exchange, angled dir

75 accurate subcutaneous glucose sensor and an infusion cannula that delivers insulin in response to me

76 Dynamic imaging during IA infusion captured the spatiotemporal dynamic of infiltra

77 regimen combining rituximab with continuous-infusion chemotherapy followed by allogeneic transplanta

78 In the high-dose single infusion cohort, 3 of 6 patients with refractory CRS con

79 weight, to a maximum of 1 x 10(8) cells per infusion (cohort A), or 2 x 10(6) cells per kg body weig

80 ht, to a maximum dose of 2 x 10(8) cells per infusion (cohort B).

81 cetin induced aggregation after desmopressin infusion compared to baseline (p < 0.001).

82 0 concentrations were needed after endotoxin infusion compared to baseline (p < 0.011).

83 oire in vitro and at early time points after infusion.CONCLUSIONSB-engineered CAR T cells expand and

84 When compared with intermittent infusion, continuous infusion was associated with a redu

85 ate of immunosuppression prior to CAR-T-cell infusion coupled with unique acute and persistent insult

86 Albumin infusion decreases the incidence of PICD and mortality i

87 g skeletal muscle during control vasodilator infusions (DeltaFVC: ACh: -31 +/- 3 and ATP: -30 +/- 4%)

88 Bilateral kainic acid (KA) infusions depressed compound AN responses by 40-70% with

89 t-curved-straight microchannels and a direct infusion (dI) micronebulizer for inductively coupled pla

90 CP infusion did not alter recipient NAb titers.

91 ve of impaired sympatholysis, and ACh or ATP infusion during mild exercise did not impact this respon

92 Direct-infusion ESI-MS showed that the tested volatile eluent s

93 e daily and durvalumab 1.5 g via intravenous infusion every 4 weeks until disease progression.

94 cure through 12 weeks following bezlotoxumab infusion experienced recurrent Clostridioides difficile

95 e for 15% technical vein of Marshall ethanol infusion failures.

96 beling with 1-(13) C(1) -acetate intravenous infusion, followed by measurement of labeled very low-de

97 saline or BQ-123 (ET(A) receptor antagonist) infusion following a 2-week withdrawal of anti-hypertens

98 Similarly, CGA infusions following cue re-exposure significantly attenu

99 ily infusions) or the same volume of placebo infusions for 10 days.

100 rted in 25 (10%) patients in the intravenous infusion group and 26 (10%) patients in the fixed-dose c

101 t led to death (urosepsis in the intravenous infusion group and acute myocardial infarction in the fi

102 ation combined with vein of Marshall ethanol infusion group compared with 38% (60/158) in the cathete

103 (34 [13%] of 252 patients in the intravenous infusion group vs 35 [14%] of 248 patients in the fixed-

104 % of the patients who received an emapalumab infusion had a response; these percentages were signific

105 howed that when using the gravity method for infusion, half of the activity is infused after 3.5 min,

106 ry properties suggested that DP and DJ fruit infusion have the potential to become a commercial healt

107 plus dacarbazine in LMS; high-dose prolonged-infusion ifosfamide in SS; etoposide plus ifosfamide in

108 ng CD19-targeted CAR-T cells: pre CAR-T-cell infusion, immediate post CAR-T-cell infusion, and long-t

109 Viremia was observed at 48 hours after the infusion in 2 of 5 participants who received placebo and

110 ent of automatic systems for control of drug infusion in anaesthesiology.

111 Following angiotensin II infusion in mice, we found that an affinity matured nano

112 emoral dP/dtmax increased by 46% after fluid infusion in preload-dependent cases (mean change = 510.6

113 ntravenous n-3 PUFA emulsion as a standalone infusion in the time sequence reported in the present st

114 s, and sensory attributes of DP and DJ fruit infusions in comparison with commercial forest fruits (F

115 nse consolidation with additional CAR T-cell infusions includes pembrolizumab to improve their effica

116 gyrus subgranular zone, and a single-Reelin infusion increased the number but not complexity of newb

117 b afferents examined and that single cocaine infusions induced biphasic responses in rEPN neurons, wi

118 Oxytocin infusion into BNSTam in stress naive mice increased soci

119 ssion of human mutant APP in mice or Abeta42 infusion into control diet-fed mice to mimic obese level

120 ith high titers of neutralizing activity for infusion into patients with COVID-19.

121 STC has a CMC in the 5-8 mM range and its infusion into the pancreatic duct is commonly used to st

122 VacA infusion invoked an immune response, as indicated by the

123 q demonstrates that clones that expand after infusion mainly originate from infused clusters with hig

124 3 weeks after adeno-associated viral (AAV) infusion, mice were exposed to 330 mug of Mn (MnCl(2) 30

125 x 10(6) cells per kg with non-cryopreserved infusion (n = 12) was 100% (complete response, 92%; part

126 shed, 21 patients were treated with a 1-hour infusion (n = 13, 8 mg/kg, once every 2 weeks and n = 8,

127 ation combined with vein of Marshall ethanol infusion (n = 185) in a 1:1.15 ratio to accommodate for

128 A placebo infusion (normal saline) was administered on study day 1

129 unit of administered activity for a therapy infusion of (90)Y-DOTA-BC8 were 0.35 +/- 0.20 cGy/MBq fo

130 educed the increase in circulating BAs after infusion of 120 mM (5%) STC into the pancreatic duct, an

131 he antidepressant-like effects of intra-mPFC infusion of 8-OH-DPAT are blocked by co-infusion of an A

132 Additionally, we examined how weekly infusion of a 20% top-load dose of PolyhHb influences gr

133 oad (low volume) and exchange (large volume) infusion of a tense quaternary state (T-State) PolyhHb,

134 ssure measurements, participants received an infusion of a US contrast agent and saline.

135 tion of endothelium-dependent signalling via infusion of ACh or ATP during moderate intensity exercis

136 nd (iv) mild or moderate handgrip exercise + infusion of ACh or ATP to augment endothelium-dependent

137 SOD1) were treated with a single intrathecal infusion of adeno-associated virus encoding a microRNA t

138 of treatment in such cases using intravenous infusion of adrenaline which has been adopted for widesp

139 Finally, micro-infusion of alpha-conotoxin AuIB (10 mum) but not alpha-

140 mPFC infusion of 8-OH-DPAT are blocked by co-infusion of an AMPA receptor antagonist or an anti-BDNF

141 ylephrine (PE; alpha(1) -agonist) during (i) infusion of an endothelium-dependent vasodilator alone (

142 Chronic infusion of angiotensin-II in atheroprone (ApoE(-/-)) mi

143 al progenitor cells using a 7-day continuous infusion of Ara-C prior to rSham or rmTBI.

144 However, infusion of autoantigen-specific T(regs) after alphaCD3

145 icipants with ASD were administered a single infusion of autologous umbilical cord blood and, as part

146 Infusion of BDNF protein adjacent to the RA of SD birds

147 and portal hypertension, 1 year of biweekly infusion of belapectin was safe but not associated with

148 s before and after acute intrarenal arterial infusion of candesartan (4.2 mug kg(-1) ) or intravenous

149 candesartan (4.2 mug kg(-1) ) or intravenous infusion of CAP (20 mg kg(-1) ).

150 tionally, we demonstrate that intra-arterial infusion of capsaicin results in a dose-related rise in

151 fic CD4CAR T cells, followed by supplemental infusion of cell-associated HIV-1 envelope (Env).

152 not manipulated, followed immediately by LA infusion of CGA.

153 regnancy-induced rise of factor levels or by infusion of coagulation factor concentrates at the time

154 Patients received a conditioning regimen, infusion of donor hematopoietic cells, then immunosuppre

155 d-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram

156 ment involves daily injections or continuous infusion of exogenous insulin aimed at regulating blood

157 hrough the imaging window during intravenous infusion of fluorescently labeled low and high molecular

158 intravenously over 5 min, followed by a 46 h infusion of fluorouracil 2400 mg/m(2) repeated every 2 w

159 We used an intragastric infusion of glucose and water to bypass the cephalic pha

160 erial infection from the developing fetus by infusion of granulysin into placental trophoblast cells

161 Vacuum assisted infusion of GSP results in a high yield (~1 mg/g) of tra

162 corroborated by the extraction of Mg in the infusion of hot water.

163 Intracerebroventricular infusion of indomethacin, an anti-inflammatory drug, mit

164 in hepatic insulin sensitivity, assessed by infusion of insulin at low rates (stages 1 and 2 of a 3-

165 During infusion of ISO in vivo, the incidence of delayed afterd

166 protocol at baseline and following a 40 min infusion of ketamine (0.5 mg/kg).

167 Intra-arterial (IA) infusion of mannitol induces osmotic blood-brain barrier

168 Decades of field studies and the infusion of molecular biological, genomic, isotopic, and

169 Infusion of neurotensin into the fourth ventricle induce

170 Intravenous infusion of Ngb-H64Q-CCC restored respiration rates to t

171 In conclusion, on-site manufacturing and infusion of non-cryopreserved LV20.19 CAR T cells were f

172 l of 190 C57BL/6J mice received a continuous infusion of norepinephrine or vasopressin via microosmot

173 ar conductance (FVC) to local intra-arterial infusion of phenylephrine (PE; alpha(1) -agonist) during

174 Although regulated, the total time of infusion of preincision antibiotics varies widely.

175 Conclusion: A faster infusion of PRRT using an infusion time of less than 5 m

176 Acute systemic administration and intra-mPFC infusion of RS67333 produced fast anxiolytic effects and

177 les: (1) NVC was assessed during intravenous infusion of saline (placebo) and the non-selective compe

178 tic pump for continuous 4-day jugular venous infusion of sEVs and determined their effects on glucose

179 Furthermore, infusion of siRNA targeting MORs specifically in mPOA bo

180 In patients with calciphylaxis (N = 14), infusion of SNF472 (~ 7 mg/kg) during hemodialysis for 1

181 d by an increase in arterial pH generated by infusion of sodium bicarbonate (NaHCO(3) ), and complete

182 In general, we found that infusion of T-State PolyhHb is more likely to decrease t

183 injury (AKI) were randomized to albumin with infusion of terlipressin (2-12 mg/day; n = 60) or noradr

184 Infusion of terlipressin gives earlier and higher respon

185 The results show that intra-mPFC infusion of the 5-HT(1A) receptor agonist 8-OH-DPAT indu

186 duced reinstatement, which was blocked by co-infusion of the CaN inhibitor, FK-506.

187 Next, we demonstrate that intrahippocampal infusion of the protein synthesis inhibitor anisomycin d

188 diabetes, we also observed that intravenous infusion of the same n-apo AI (CSL111, 80 mg/kg) similar

189 ls), which were administered as a sequential infusion of two components (CD8(+) and CD4(+) CAR(+) T c

190 Patients received siltuximab infusions of 11 mg/kg every 3 weeks (which could be exte

191 Thirty-five fluid infusions of 500 mL normal saline.

192 ind manner, to groups that received biweekly infusions of belapectin 2 mg/kg (n = 54), 8 mg/kg (n = 5

193 We found that intra-LA infusions of CGA following cue extinction or reconsolida

194 Intra-NAc infusions of Cre-inducible viral vectors containing stim

195 BALB/cJ dams were exposed to five infusions of CRF or saline into the BNST in the first we

196 All other subjects received intravenous infusions of CYP-001 on days 0 and 7, at a dose level of

197 Last, intra-BLA infusions of d-amphetamine also intensified lever-pressi

198 n be effectively inhibited by peritransplant infusions of donor apoptotic cells in combination with a

199 Treatment cycles consisted of 3 weekly infusions of EBV-CTLs and 3 weeks of observation.RESULTS

200 Consistent with our systemic studies, infusions of exendin-4 directly into the accumbens shell

201 imepiride 1 mg) or placebo, combined with 2) infusions of GIP (1.5 pmol/kg/min), GLP-1 (0.5 pmol/kg/m

202 The infusions of ketamine were relatively well tolerated com

203 Participants received primed, continuous infusions of L-[ring-2H5]phenylalanine and ingested eith

204 Intra-CeA infusions of N/OFQ (1 mug per site) reversed the escalat

205 Bilateral infusions of pioglitazone (0, 5, and 10 mug/mul) in the

206 IED; this effect was blocked with intra-BLA infusions of propranolol.

207 idneys received 30-minute renal interstitial infusions of vehicle followed by C-21 (20, 40, and 60 ng

208 he surgical microscope with anterior chamber infusion offers the ergonomic and optical advantages of

209 To quantify the effects of infusion on BBB opening, we calculated the MRI contrast

210 The effect of 72-h glucose infusion on insulin secretion and insulin sensitivity wa

211 l, we evaluated the effects of acute nitrite infusion on muscle force and skeletal muscle oxidative m

212 f repeated or single intrahippocampal Reelin infusions on measures of depressive-like behavior, cogni

213 art, 24 patients received MP0250 as a 3-hour infusion once every 2 weeks at five different dose level

214 tion followed by CTL019 as either a one-time infusion or fractionated infusions split over 3 days (da

215 rticipants were given either dexmedetomidine infusion or saline placebo started before the surgical i

216 lowed by 100 mg on days 2-10 in single daily infusions) or the same volume of placebo infusions for 1

217 o was 100 mL normal saline, both given as an infusion over 15 min.

218 Extended therapy with biannual rituximab infusions over 18 months was associated with a lower inc

219 erals and soluble sugars were observed in FF infusions (P < 0.05).

220 bioside was detected only in DP and DJ fruit infusions (P < 0.05).

221 Medicare does not reimburse for home infusion; patients requiring outpatient parenteral antim

222 VIII was reduced from 155.5 infusions to 0.5 infusions per year.

223 r VIII was reduced from 138.5 infusions to 0 infusions per year.

224 placebo bolus and in-hospital placebo 8-hour infusion (placebo group; n = 309).

225 stemic administration (typically intravenous infusion), precluding the feasible dosing of antibody co

226 cRNA-seq) to profile CD8(+) CAR-T cells from infusion products (IPs) and blood of patients undergoing

227 ellular and molecular features of CAR T cell infusion products contributes to variation in efficacy a

228 and counterregulatory hormone (epinephrine) infusion profoundly stimulated adipocyte lipolysis and s

229 samples obtained following a stable isotope infusion protocol of (13)C(2)-oxalate and 1-(13)C-glycol

230 iment was performed, simulating the standard-infusion protocol using the gravity method.

231 All patients receiving PRRT using the fast-infusion protocol were included.

232 inical toxicity after PRRT when using a fast-infusion protocol with a maximum infusion time of 5 min.

233 ia chronomodulated schedules delivered by an infusion pump into the hepatic artery were mathematicall

234 VDR activation greatly increased the glucose infusion rate, while hepatic glucose production was rema

235 However, when infusion rates exceeded 20 ul/kg/min, signs of injury oc

236 eased risk of serious adverse events such as infusion reactions and anaphylaxis.

237 All-grade infusion reactions were less frequent with acalabrutinib

238 eutic concentration in 460 min while aspirin infusion reduces that time to 330 min.

239 Time-condensed continuous-infusion reinduction followed by stem cell transplantati

240 atigue (33.3%), nausea/vomiting (33.3%), and infusion-related reaction (26.7%).

241 adverse events were anaemia (four [4%]) and infusion-related reactions (three [3%]).

242 No grade 3-4 infusion-related reactions occurred.

243 Infusion-related reactions were more common with AK002 t

244 of patients with hypersensitivity reactions, infusion-related reactions, and other adverse events wer

245 on of in-hospital mortality, length of stay, infusion-related reactions, and thrombotic event occurre

246 he reward-related brain regions during water infusion relative to glucose infusion.

247 that regulate the fate of CAR-T cells after infusion remain poorly understood.

248 requiring continuous vasoactive or diuretic infusion, respiratory support, or mechanical circulatory

249 ty of newborn neurons, while repeated Reelin infusions restored both.

250 Gingerols infusion retarded the deterioration of all quality param

251 Using direct infusion-shotgun proteome analysis (DI-SPA) by data-inde

252 Nitrite infusion significantly increased both nitrite and nitrat

253 Two years after infusion, six participants (who had received 4x10(13) vg

254 s either a one-time infusion or fractionated infusions split over 3 days (day 1, 10%; day 2, 30%; day

255 s a continuous patient monitoring during the infusion, staff training on management of adverse effect

256 Herein, we describe a direct infusion strategy for CL profiling from total lipid extr

257 mediated currents in the PVN following AngII infusion, suggesting a mechanism whereby TNFR1 activatio

258 to 2 intravenous n-3 PUFA or saline control infusions the night before and the morning after surgery

259 ing targeted medial prefrontal cortex (mPFC) infusions, these effects were localised to the mPFC.

260 transporter ratio (P = 3.6 x 10-4), the MTX infusion time (P = 1.5 x 10-3), FPGS mRNA expression (P

261 a quality improvement algorithm to optimize infusion time compliance.

262 e retrospective data here suggest a critical infusion time for infection reduction (24.6 min before i

263 here is no evidence to explicitly support an infusion time of 30 min.

264 sing a fast-infusion protocol with a maximum infusion time of 5 min.

265 nclusion: A faster infusion of PRRT using an infusion time of less than 5 min is safe and feasible in

266 s study aims to investigate the safety of an infusion time of less than 5 min.

267 nificantly noncompliant, reduced preincision infusion time, significantly predicted SSI (<24.6 min in

268 dministration protocols prescribing a 30-min infusion time.

269 Vancomycin infusion times that were not compliant with national sta

270 specially for multiantibody deliveries, long infusion times, and production issues could limit the us

271 gs) increased from a median of 6% before MIC infusion to 20% on day 180, which was 19- and 68-fold hi

272 exogenous factor VIII was reduced from 138.5 infusions to 0 infusions per year.

273 an use of factor VIII was reduced from 155.5 infusions to 0.5 infusions per year.

274 Three years after infusion, two participants (one who had received 6x10(12

275 When administered via a continuous infusion, vancomycin is associated with a 53% reduction

276 ality included age <30 days, CHD, vasoactive infusions, ventricular tachycardia, mechanical ventilati

277 Adjunctive vein of Marshall (VOM) ethanol infusion (VOM-Et) can facilitate acute MI block.

278 median time of relapse after the most recent infusion was 2.6 (0.6-5.8) and 7 (0.8-13) months, respec

279 Alcohol use following the infusion was assessed with timeline followback method, w

280 pared with intermittent infusion, continuous infusion was associated with a reduction in acute kidney

281 A single ketamine infusion was found to improve measures of drinking in pe

282 Propofol infusion was gradually increased while auditory stimuli

283 unds in breads, the addition of green coffee infusion was much more relevant (19.1-fold) than enzymat

284 The order of infusion was randomized, counterbalanced and single blin

285 IdeS treatment before AAV vector infusion was safe and resulted in enhanced liver transdu

286 d by cell-free DNA sequencing at day 7 after infusion was significantly associated with clinical resp

287 Results: (89)Zr-IAB22M2C infusion was well tolerated, with no immediate or delaye

288 ities and overall likeness score of DP or DJ infusion were comparable with the commercial FF infusion

289 Viral infusions were bilateral in rNTS.

290 se) with follow-up out to day 360.RESULTSMIC infusions were extremely well tolerated.

291 ycodone (6 hours/day, 14 days) in context A; infusions were paired with discrete tone-light cues.

292 RMD infusions were safe but did not increase plasma viremia

293 Infusions were well tolerated, with no participants remo

294 In contrast IA infusion with an intact BBB resulted in 3.56 +/- 1.06%ID

295 Intravenous infusion with either 5 mg of zoledronic acid in a 100-mL

296 A second infusion with human FIX and FX, administered 5 minutes b

297 (1.5 mg/kg, intraperitoneally) or intra-mPFC infusion with the 5-HT(4)R agonist, RS67333 (0.5 mug/sid

298 re control using continuous anterior chamber infusion) with those of external drainage (drainage of s

299 t attainment when compared with intermittent infusion without influencing overall mortality.

300 ch is consolidated with four more CAR T-cell infusions without lymphodepletion.